» Articles » PMID: 3934317

Escherichia Coli K51 and K93 Capsular Polysaccharides Are Crossreactive with the Group A Capsular Polysaccharide of Neisseria Meningitidis. Immunochemical, Biological, and Epidemiological Studies

Overview
Journal J Exp Med
Date 1985 Dec 1
PMID 3934317
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Eleven Escherichia coli strains, crossreactive with the capsular polysaccharide (CPS) of Neisseria meningitidis group A (GrA), were detected among 645 stool isolates from healthy families in Cairo, Egypt. 10 of these strains were of the O107:K93:H27 or O107:K93:SP serotypes and may be considered descendents of a single bacterium or as a clone. The remaining crossreactive strain was of the O7:K51:H18 serotype. None of the 11 strains produced enterotoxins and none were enteroinvasive. The purified CPS of these E. coli strains, as well as a polysaccharide (PS) from B. pumilis, strain Sh17, precipitated with equine GrA (H49) antiserum. A partial identity between the E. coli K93, K51 and Sh17 PS on the one hand and the GrA CPS on the other was observed by double immunodiffusion when reacted against the H49 antiserum. Four K93 strains and one K51 strain were found among 320 E. coli strains from patients at the Clinical Center, National Institutes of Health, and three K93 strains were found in 105 stool samples from children in Copenhagen. The data from these three surveys suggest that these crossreactive E. coli are common organisms and could serve as a stimulus for "natural" GrA CPS antibodies. Quantitative precipitation analysis showed that K51, K93, and Sh17 PS precipitated 25, 46.8, and 50% of H49 antibodies, respectively. Absorption of H49 antiserum with the GrA CPS removed its precipitating activity with the E. coli K93, K51, and Sh17 PS. Absorption of H49 antiserum with either K51 CPS or Sh17 PS removed the homologous crossreactivity only, whereas K93 CPS absorbed both K93 and K51 reactivities. Antibodies, raised by intravenous injection of formalinized E. coli K93 or K51 cells into rabbits, precipitated with GrA CPS and were bactericidal against GrA meningococci. The crossreaction between the E. coli K93 and the GrA CPS was unexpected since these two CPS are compositionally so dissimilar.

Citing Articles

Efficacy and Effectiveness of the Meningococcal Conjugate Group A Vaccine MenAfriVac in Preventing Recurrent Meningitis Epidemics in Sub-Saharan Africa.

Viviani S Vaccines (Basel). 2022; 10(4).

PMID: 35455366 PMC: 9027557. DOI: 10.3390/vaccines10040617.


Induction of Susceptibility to Disseminated Infection with IgA1 Protease-Producing Encapsulated Pathogens Streptococcus pneumoniae, Haemophilus influenzae Type b, and Neisseria meningitidis.

Kilian M, Husby S, Andersen J, Moldoveanu Z, Skov Sorensen U, Reinholdt J mBio. 2022; 13(3):e0055022.

PMID: 35420467 PMC: 9239265. DOI: 10.1128/mbio.00550-22.


Safety of Multiple Vaccinations and Durability of Vaccine-Induced Antibodies in an Italian Military Cohort 5 Years after Immunization.

Ferlito C, Visco V, Biselli R, Cattaruzza M, Carreras G, Salerno G Biomedicines. 2022; 10(1).

PMID: 35052686 PMC: 8773007. DOI: 10.3390/biomedicines10010006.


A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis Belt.

Manigart O, Trotter C, Findlow H, Assefa A, Mihret W, Moti Demisse T PLoS One. 2016; 11(2):e0147928.

PMID: 26872255 PMC: 4752490. DOI: 10.1371/journal.pone.0147928.


Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac.

Tang Y, Plikaytis B, Preziosi M, Borrow R Clin Infect Dis. 2015; 61 Suppl 5:S531-9.

PMID: 26553685 PMC: 4639503. DOI: 10.1093/cid/civ601.


References
1.
Peltola H . Meningococcal disease: still with us. Rev Infect Dis. 1983; 5(1):71-91. DOI: 10.1093/clinids/5.1.71. View

2.
Frasch C, ROBBINS J . Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model. J Exp Med. 1978; 147(3):629-44. PMC: 2184206. DOI: 10.1084/jem.147.3.629. View

3.
Austrian R . Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev Infect Dis. 1981; 3 Suppl:S1-17. DOI: 10.1093/clinids/3.supplement_1.s1. View

4.
Griffiss J . Epidemic meningococcal disease: synthesis of a hypothetical immunoepidemiologic model. Rev Infect Dis. 1982; 4(1):159-72. DOI: 10.1093/clinids/4.1.159. View

5.
Myerowitz R, Gordon R, Robbins J . Polysaccharides of the genus Bacillus cross-reactive with the capsular polysaccharides of Diplococcus pneumoniae type 3, Haemophilus influenzae type b, and Neisseria meningitidis group A. Infect Immun. 1973; 8(6):896-900. PMC: 422947. DOI: 10.1128/iai.8.6.896-900.1973. View